Nox isoforms in vascular pathophysiology: Insights from transgenic and knockout mouse models

Redox Report

Volumn 15, Issue 2, 2010, Pages 50-63

  Rivera, Jennifer ^a,b   Sobey, Christopher G ^a   Walduck, Anna K ^b   Drummond, Grant R ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Mouse models; Noxi soforms; ROS; Vascular pathophysiology

Indexed keywords

OXIDOREDUCTASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; UNCLASSIFIED DRUG;

ARTERY INJURY; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR FUNCTION; CELLULAR DISTRIBUTION; CEREBROVASCULAR ACCIDENT; CHRONIC GRANULOMATOUS DISEASE; DIABETES MELLITUS; DISEASE MODEL; DNA MODIFICATION; ENDOTHELIAL DYSFUNCTION; ENZYME STRUCTURE; HUMAN; HYPERTENSION; KNOCKOUT MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; TRANSGENIC MOUSE; VASCULAR DISEASE;

ANIMALS; HUMANS; ISOENZYMES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NADPH OXIDASE; REACTIVE OXYGEN SPECIES;

ANIMALIA; MUS;

EID: 77952503290     PISSN: 13510002     EISSN: 17432928     Source Type: Journal    
DOI: 10.1179/174329210X12650506623401     Document Type: Review

References (78)

1. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007;87:245-313.
2. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008;120:254-291.
3. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008;10:1713-1765.
4. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol 2003;30:849-854.
5. Malle E, Marsche G, Arnhold J, Davies MJ. Modification of lowdensity lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006;1761:392-415.
6. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
7. Lassegue B, Clempus RE. Vascular NAD (P) H oxidases: specific features, expression, and regulation. Am J Physiol 2003;285: R277-R297.
8. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 2002;397:342-344.
9. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52:741-744.
10. Rossi F, Zatti M. Biochemical aspects of phagocytosis in polymorphonuclear leucocytes. NADH and NADPH oxidation by the granules of resting and phagocytizing cells. Experientia 1964;20:21-23.
11. Kawahara T, Ritsick D, Cheng G, Lambeth JD. Point mutations in the proline-rich region of p22phox are dominant inhibitors of Nox1- and Nox2-dependent reactive oxygen generation. J Biol Chem 2005;280:31859-31869.
12. Hordijk PL. Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006;98:453-462.
13. Bokoch GM, Zhao T. Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal 2006;8:1533-1548.
14. Van Buul JD, Fernandez-Borja M, Anthony EC, Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 2005;7:308-317.
15. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002;277:19952-19960.
16. Chamseddine AH, Miller Jr FJ. Gp91phox contributes to NADPH oxidase activity in aortic fibroblasts but not smooth muscle cells. Am J Physiol 2003;285: H2284-H2289.
17. Touyz RM, Chen X, Tabet F et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD (P) H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002;90:1205-1213.
18. Lassegue B, Sorescu D, Szocs K et al. Novel gp91 (phox) homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II- induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001;88:888-894.
19. Kalinina N, Agrotis A, Tararak E et al. Cytochrome b558-dependent NAD (P) H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2002;22:2037-2043.
20. Suh YA, Arnold RS, Lassegue B et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401:79-82.
21. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2004;24:677-683.
22. Ago T, Kitazono T, Kuroda J et al. NAD (P) H oxidases in rat basilar arterial endothelial cells. Stroke 2005;36:1040-1046.
23. Banfi B, Clark RA, Steger K, Krause KH. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 2003;278:3510-3513.
24. Hanna IR, Hilenski LL, Dikalova A et al. Functional association of Nox1 with p22phox in vascular smooth muscle cells. Free Radic Biol Med 2004;37:1542-1549.
25. Ellmark SH, Dusting GJ, Fui MN, Guzzo-Pernell N, Drummond GR. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res 2005;65:495-504.
26. Wingler K, Wunsch S, Kreutz R, Rothermund L, Paul M, Schmidt HH. Upregulation of the vascular NAD (P) H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med 2001;31:1456-1464.
27. Katsuyama M, Fan C, Yabe-Nishimura C. NADPH oxidase is involved in prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells: induction of NOX1 by PGF2alpha. J Biol Chem 2002;277:13438-13442.
28. Manea A, Irina Tanase L, Raicu M, Simionescu M. JAK/STAT signaling pathway regulates Nox1 and Nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2010;30:105-112.
29. Sorescu GP, Song H, Tressel SL et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004;95:773-779.
30. Matsuno K, Yamada H, Iwata K et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 2005;112:2677-2685.
31. Wendt MC, Daiber A, Kleschyov AL et al. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic Biol Med 2005;39:381-391.
32. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD (P) H oxidase in kidney. Proc Natl Acad Sci USA 2000;97:8010-8014.
33. Ago T, Kitazono T, Ooboshi H et al. Nox4 as the major catalytic component of an endothelial NAD (P) H oxidase. Circulation 2004;109:227-233.
34. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006;18:69-82.
35. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes R P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004;279:45935-45941.
36. Moe KT, Aulia S, Jiang F et al. Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med 2006;10:231-239.
37. Park HS, Chun JN, Jung H Y, Choi C, Bae YS. Role of NADPH oxidase 4 in lipopolysaccharide-induced proinflammatory responses by human aortic endothelial cells. Cardiovasc Res 2006;72:447-455.
38. Banfi B, Molnar G, Maturana A et al. A Ca (2+) -activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 2001;276:37594-37601.
39. BelAiba RS, Djordjevic T, Petry A et al. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 2007;42:446-459.
40. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassegue B, Griendling KK. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 2008;45:329-335.
41. Guzik TJ, Chen W, Gongora MC et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 2008;52:1803-1809.
42. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994;11:95-102.
43. Gavazzi G, Banfi B, Deffert C et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 2006;580:497-504.
44. Dikalova A, Clempus R, Lassegue B et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005;112:2668-2676. (Pubitemid 41532604)
45. Yogi A, Mercure C, Touyz J et al. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 2008;51:500-506.
46. Wang HD, Xu S, Johns DG et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001;88:947-953.
47. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004;109:1795-1801.
48. Touyz RM, Mercure C, He Y et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 2005;45:530-537.
49. Carlstrom M, Lai E Y, Ma Z, Patzak A, Brown RD, Persson AE. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am J Physiol 2009;296: R72-R79.
50. Bendall JK, Rinze R, Adlam D et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelialtargeted Nox2 transgenic mice. Circ Res 2007;100:1016-1025.
51. Landmesser U, Cai H, Dikalov S et al. Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002;40:511-515.
52. Guzik TJ, Hoch NE, Brown KA et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007;204:2449-2460.
53. Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003;111:1201-1209.
54. Miriyala S, Gongora Nieto MC, Mingone C et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006;113:2818-2825.
55. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004;24:1006-1014.
56. Plump AS, Smith JD, Hayek T et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-353.
57. Barry-Lane PA, Patterson C, van der Merwe M et al. p47phox is required for atherosclerotic lesion progression in ApoE (-/-) mice. J Clin Invest 2001;108:1513-1522.
58. Hsich E, Segal BH, Pagano PJ et al. Vascular effects following homozygous disruption of p47 (phox): An essential component of NADPH oxidase. Circulation 2000;101:1234-1236.
59. Vendrov AE, Hakim ZS, Madamanchi NR, Rojas M, Madamanchi C, Runge MS. Atherosclerosis is attenuated by limiting superoxide generation in both macrophages and vessel wall cells. Arterioscler Thromb Vasc Biol 2007;27:2714-2721.
60. -/- mice. Am J Physiol 2010;298: H24-H32.
61. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke J W, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2000;20:1529-1535.
62. Sheehan AL, Takapoo M, Banfi B, Miller Jr FJ. Role for Nox1 NADPH oxidase in atherosclerosis. Circulation 2007;116: II-244-c-.
63. Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets 2008;9:251-260.
64. Szocs K, Lassegue B, Sorescu D et al. Upregulation of Nox-based NAD (P) H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 2002;22:21-27.
65. Lee M Y, San Martin A, Mehta PK et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injuryinduced neointimal formation. Arterioscler Thromb Vasc Biol 2009;29:480-487.
66. Niu XL, Madamanchi NR, Vendrov AE et al. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010;121:549-559.
67. Chen Z, Keaney Jr JF, Schulz E et al. Decreased neointimal formation in Nox2-deficient mice reveals a direct role for NADPH oxidase in the response to arterial injury. Proc Natl Acad Sci USA 2004;101:13014-13019.
68. Chen H, Song YS, Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab 2009;29:1262-1272.
69. Kahles T, Luedike P, Endres M et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 2007;38:3000-3006.
70. Kunz A, Anrather J, Zhou P, Orio M, Iadecola C. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab 2007;27:545-551.
71. Walder CE, Green SP, Darbonne WC et al. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 1997;28:2252-2258.
72. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 2009;156:680-688.
73. Brait VH, Jackman KA, Walduck AK et al. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 2010; Epub ahead of print.
74. Jackman KA, Miller AA, Drummond GR, Sobey CG. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 2009;1286:215-220.
75. Huang CK, Zhan L, Hannigan MO, Ai Y, Leto TL. P47 (phox) - deficient NADPH oxidase defect in neutrophils of diabetic mouse strains, C57BL/6J-m db/db and db/+. J Leukoc Biol 2000;67:210-215.
76. Hummel KP, Coleman DL, Lane P W. The influence of genetic background on expression of mutations at the diabetes locus in the mouse. I. C57BL-KsJ and C57BL-6J strains. Biochem Genet 1972;7:1-13.
77. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003;15:578-584.
78. Violi F, Sanguigni V, Carnevale R et al. Hereditary deficiency of gp91 (phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009;120:1616-1622.